15-deoxy-Δ12,14-PGJ2 induces synoviocyte apoptosis and suppresses adjuvant-induced arthritis in rats

Journal of Clinical Investigation

Volumn 106, Issue 2, 2000, Pages 189-197

  Kawahito, Yutaka ^a   Kondo, Motoharu ^a   Tsubouchi, Yasunori ^a   Hashiramoto, Akira ^a   Bishop Bailey, David ^b,c   Inoue, Ken Ichiro ^a   Kohno, Masataka ^a   Yamada, Ryoji ^a   Hla, Timothy ^b   Sano, Hajime ^a  

^a KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

^b UNIVERSITY OF CONNECTICUT HEALTH CENTER   (United States)

^c QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

DELTA12 PROSTAGLANDIN J2; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIINFLAMMATORY ACTIVITY; APOPTOSIS; ARTICLE; DRUG MECHANISM; FEMALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; RHEUMATOID ARTHRITIS; SYNOVIOCYTE;

EID: 0033925031     PISSN: 00219738     EISSN: None     Source Type: Journal    
DOI: 10.1172/JCI9652     Document Type: Article

References (56)

1. Feldmann, M., Brennan, F.M., and Maini, R.N. 1996. Rheumatoid arthritis. Cell. 85:307-310.
2. Koch, A.E. 1998. Angiogenesis: implications of rheumatoid arthritis. Artbritis Rheum. 41:951-962.
3. Clancy, R.M., Amin, A.R., and Abramson, S.B. 1998. The role of nitric oxide in inflammation and immunity. Arthritis Rheum. 41:1141-1151.
4. Hopkins, S.J., and Meager, A. 1988. Cytokines in synovial fluid: II. The presence of tumour necrosis factor and interferon. Clin. Exp. Immunol. 73:88-92.
5. Fontana, A., et al. 1982. Inrerleukni-1 activity in the synovial fluid of patients with rheumatoid arthritis. Rheumatol. Int. 2:49-53.
6. Moreland, L.W., et al. 1997. Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor (p75)-Fc fusion protein. N. Engl. J. Med. 337:141-147.
7. Elliott, M.J., et al. 1994. Randomized double-blind comparison of chimeric monoclonal antibody to tumor necrosis factor α(cA2) versus placebo in rheumatoid arthritis. Lancet. 344:1105-1110.
8. Campion, G.V., et al. 1996. Dose-range and dose-frequency study of recombinant human interleukin-1 receptor antagonist in patients with rheumatoid arthritis. Arthritis Rheum. 39:1092-1101.
9. Vaishnaw, A.K., Mcnally, J.D., and Elkon, K.B. 1997. Apoptosis in the rheumatic diseases. Arthritis Rheum. 40:1917-1927.
10. Fassbender, H.G., and Gay, S. 1988. Synovial processes in rheumatoid arthritis. Scand J. Rheumatol. 76:1-7.
11. Mangelsdorf, D.J., et al. 1995. The nuclear receptor superfamily: the second decade. Cell. 83:835-839.
12. Issemann, I., and Grenn, S. 1990. Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators. Nature. 347:645-050.
13. Gearing, K.L., Gottlicher, M., Teboul, M., Widmark, E., and Gustafsson, J.-Ǎ. 1993. Interaction of the peroxisome-proliferator-activated receptor and retinoid X receptor. Proc. Natl. Acad. Sci. USA. 90:1440-1444.
14. Kliewer, S.A., et al. 1994. Differential expression and activation of a family of murine peroxisome proliferator-activated receptors. Proc. Natl. Acad. Sci. USA. 91:7355-7359.
15. Sher, T., Yi, H.-F., McBride, O.W., and Gonzalez, F.J. 1993. cDNA cloning, chromosomal mapping, and functional characterization of the human peroxisome proliferator activated receptor. Biochemistry. 32:5598-5604.
16. Braissant, O., Foufelle, F., Scotto, C., Dauca, M., and Wahli, W. 1996. Differential expression of peroxisome proliferator-activated receptors (PPARs): tissue distribution of PPAR-α, -β, and -γ in the adult rat. Endocrinol. 137:354-366.
17. Schmidt, A., et al. 1992. Identification of a new member of the steroid hormone receptor superfamily that is accivated by peroxisonic proliferator and fatty acid. Mol. Endocrinol. 6:1634-1641.
18. He, T.C., Chan, T.A., Vogelstein, B., and Kinzler, K.W. 1999. PPARδ is an APC-regulated target of nosteroidal anti-inflammatory drugs. Cell. 99:335-345.
19. Tontonoz, P., Hu, E., and Spiegelman, B.M. 1994. Stimulation of adipogenesis in fibroblasts by PPARγ2, a lipid-activated transcription factor. Cell. 79:1147-1156.
20. Serhan, C.N. 1996. Inflammation. Signalling the fat controller. Nature. 384:23-24.
21. Devchand, P.R., et al. 1996. The PPARα-leukotriene B4 pathway to inflammation control. Nature. 384:39-43.
22. Greene, M.E., et al. 1995. Isolation of the human peroxisome proliferator-activated receptor γ cDNA: expression in hematopoietic cells and chromosomal mapping. Gene Expr. 4:281-299.
23. Clark, R.B., et al. 2000. The nuclear receptor PPARγ and immunoregulation: PPARγ mediates inhibition of helper T cell responses. J. Immunol. 164:1364-1371.
24. Ricote, M., Li, A.C., Willson, T.M., Kelly, C.J., and Glass, C.K. 1998. The peroxisome proliferator-activated receptor-γ is a negative regulator of macrophage activation. Nature. 391:79-82.
25. Jiang, C., Ting, A.T., and Seed, B. 1998. PPAR-γ agonists inhibit production of monocyte inflammatory cytokines. Nature. 391:82-86.
26. Sarraf, P., et al. 1998. Differentiation and reversal of malignant changes in colon cancer through PPARγ. Nat. Med. 4:1046-1052.
27. Kubota, T., et al. 1998. Ligand for peroxisome-proliferator activated receptor γ(Troglitazone) has potent antitumor effect against human prosrate cancer in vitro and in vivo. Cancer Res. 58:3344-3352.
28. Elstner, E., et al. 1998. Ligands for peroxisome-proliferator activated receptor γ and retinoic acid receptor inhibit growth and induce apoptosis of human breast cancer cells in vitro and in BNX mice. Proc. Natl. Acad. Sci. USA. 95:3806-8811.
29. Chinetti, G., et al. 1998. Activation of peroxisome-activated receptor α and γ induces apoptosis of human monocyte-derived macrophages J. Biol. Chem. 273:25573-25580.
30. Altoik, S., Xu, M., and Spiegelman, B.M. 1997. PPARγy induces cell cycle withdrawal: inhibition of E2F/DP DNA binding activity via down-regulation of PP2A. Genes Dev. 11:1987-1998.
31. 2 J. Biol. Chem. 274:17042-17048.
32. Forman, B.M., Chen, J., and Evans, R.M. 1997. Hypolipidemic drugs, polyunsaturated fatty acids, and eicosanoids are ligands for peroxisome proliferator-activated receptors α and δ. Proc. Natl. Acad. Sci. USA. 94:4312-4317.
33. Kremer, J.M., et al. 1985. Effects of manipulation of dietary fatty acids on clinical manifestations of rheumatoid arthritis. Lancet. 1:184-187.
34. Kremer, J.M., et al. 1995. Effects of high-dose fish oil on rheumatoid arthritis after stopping nonsteroidal antiinflammatory drugs. Arthritis Rheum. 38:1107-1114.
35. Lehmann, J.M., Lenhard, J.M., Oliver, B.B., Ringold, G.M., and Kliewer, S.A. 1997. Peroxisome proliferator-activated receptors α and γ are activated by indomethacin and other non-steroidal anti-inflammatory drugs. J. Biol. Chem. 272:3406-3410.
36. Meade, L.A., Smith, W.L., and DeWitt, D.L. 1993. Differential inhibition of prostaglandin endoperoxide synthase (cyclooxygenase) isozymes by aspirin and other non-steroidal anti-inflammatory drugs. J. Biol. Chem. 268:6610-6614.
37. Miossec, P., and van den Berg, W. 1997. Th1/Th2 cytokine balance in arthritis. Arthritis Rheum. 40:2105-2115.
38. Huang, J.T., et al. 1999. Interleukin-4-dependent production of PPAR-γ ligands in microphage by 12/15-lipoxygenase. Nature. 400:378-382.
39. Sano, H., et al. 1992. In vivo cyclooxygenase expression in synovial tissues of patients with rheumatoid arthritis and osteoarthritis and rats with adjuvant and streptococcal cell wall arthritis. J. Clin. Invest. 89:97-108.
40. Hashiramoto, A., et al. 1999. C-myc antisense deoxyoligonucleotide can induce apoptosis and Fas downregulation in rheumatoid synoviocyte. Arthritis Rheum. 42:954-962.
41. Auboeuf, D., et al. 1997. Tissue distribution and quantification of the expression of mRNAs of peroxisome proliferator-activated receptors and liver X receptor-α in humans: no alteration in adipose tissue of obese and NIDDM patients. Diabetes. 46:1319-1327.
42. Yamada, R., et al. 1999. Auranofin inhibits interleukin-1β-induced transcript of cyclooxygenase-2 on cultured human synoviocytes. Eur. J. Pharmacol. 385:71-79.
43. Kawahito, V., et al. 1998. Localization of quantitative trait loci regulating adjuvant induced arthritis: evidence for genetic factors common to multiple autoimmune diseases. J. Immunol. 161:4411-4419.
44. INK4a senescence gene as a new therapeutic strategy for the treatment of rheumatoid arthitis. Nat. Med. 5:760-767.
45. Tontonoz, P., Nagy, L., Alvarez, J.G.A., Thomazy, V.A., and Evans, R.M. 1998. PPARγ promote monocyte/macrophage differentiation and uptake of oxidized LDL. Cell. 93:241-252.
46. Xin, X., Yang, S., Kowalski, J., and Gerritsen, M.E. 1999. Peroxisome proliferator-acrivated receptor γ ligands are potent inhibitors of angiogenesis in vitro and in vivo. J. Biol. Chem. 274:9116-9121.
47. Giles, H., and Leff, P. 1988. The biology and pharmacology of PGD2. Prostaglandins. 35:277-300.
48. Brock, T.G., McNish, R.W., and Peters-Golden, M, 1999. Arachidonic acid is preferentially metabolized by cyclooxygenase-2 to prostacyclin and prostaglandin E2. J. Biol. Chem. 274:11660-11666.
49. Hirata, Y., et al. 1988. Occurrence of 9-deoxy-Δ9,Δ12-13, 14-dihydro-prostaglandin D2 in human urine. J. Biol. Chem. 263:16619-16625.
50. Gilroy, D.W., et al. 1999. Inducible cyclooxygense may have antiinflammatory properties. Nat. Med. 5:698-701.
51. 2 formed in human plasma. Proc. Natl. Acad. Sci. USA. 81:1317-1321.
52. 2 and related compounds: an update. Prostaglandins Leukot. Essent. Fatty Acids. 47:1-12.
53. Narumiya, S., Ohno, K., Fijiwara, M., and Fukushima, M. 1986. Site and mechanism of growth inhibition by prostaglandins. II. Temperature-dependent transfer of a cyclopentenone prostaglandin to nuclei. J. Phamacol. Exp. Ther. 239:506-511.
54. Rossi, A., et al. 2000. Anti-inflammatory cyclopentenone prostaglandins are direct inhibitors of IκB kinase. Nature. 403:103-118.
55. Straus, D.S., et al. 2000. 15-Deoxy-δ12, 14-prostaglandin J2 inhibits multiple steps in the NF-κB signaling pathway. Proc. Natl. Acad. Sci. USA. 97:4844-4849.
56. Imura, H. 1998. A novel antidiabetic drug, troglitazone: reason for hope and concern. N. Engl. J. Med. 338:908-909.